Neoantigen heterogeneity: A key driver of immune response and sensitivity to immune checkpoint blockade?

Immunotherapy

Volumn 8, Issue 7, 2016, Pages 763-766

  Furness, Andrew J S ^a,b   Quezada, Sergio A ^a   Peggs, Karl S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CTLA 4; heterogeneity; neoantigens; PD 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PHARMACOLOGICAL BIOMARKER; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL HETEROGENEITY; DRUG SENSITIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NEOANTIGEN HETEROGENEITY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; ANIMAL; CELLULAR IMMUNITY; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM; PATIENT SELECTION; PROCEDURES; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; UNITED KINGDOM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B7-H1 ANTIGEN; BIOMARKERS, PHARMACOLOGICAL; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PATIENT SELECTION; PRECISION MEDICINE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84976892425     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0064     Document Type: Review

References (33)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
3. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375-384 (2015).
4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 320-330 (2015).
5. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a Phase 1 trial. Lancet 384(9948), 1109-1117 (2014).
6. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase 2 trial. Lancet Oncol. 16(8), 908-918 (2015).
7. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23-34 (2015).
9. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676-1680 (1988).
10. Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J. Immunol. Baltim. Md 148(2), 638-643 (1992).
11. Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. Emphas. Tumor Immunol. 13(1), 18-30 (1993).
12. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
13. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180(1), 35-42 (1994).
14. Brichard V, Van Pel A, Wölfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178(2), 489-495 (1993).
15. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl Acad. Sci. USA 91(14), 6458-6462 (1994).
16. June CH. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117(6), 1466-1476 (2007).
17. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily-CTLA-4. Nature 328(6127), 267-270 (1987).
18. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996).
19. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33(17), 1889-1894 (2015).
20. Hodi S, Kluger H, Sznoi M, et al. Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a Phase I trial [abstract]. Proceedings of: The 107th Annual Meeting of the American Association for Cancer Research. LA, USA, 16-20 April 2016 AACR 2016, Abstract nr. CTOO1.
21. Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res. 68(3), 889-892 (2008).
22. Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081-1091 (2012).
23. Robbins PF, Lu Y-C, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19(6), 747-752 (2013).
24. Lu Y-C, Yao X, Li YF, et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. Baltim. Md. 190(12), 6034-6042 (2013) (1950).
25. Gilboa E. The makings of a tumor rejection antigen. Immunity 11(3), 263-270 (1999).
26. Van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31(32), e439-e442 (2013).
27. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189-2199 (2014).
28. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124-128 (2015).
29. Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350(6257), 207-211 (2015).
30. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
31. De Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346(6206), 251-256 (2014).
32. McGranahan N, Furness AJS, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280), 1463-1469 (2016).
33. Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade Ther. Immun. 44(2), 343-354 (2016).